Advertisement
The Active Leptospermum Honey product used in the study, Comvita'sWoundCare18+, has since been rebranded to MEDIHONEY.
To view the abstract of the study, please click:
Advertisement
http://www.ncbi.nlm.nih.gov/pubmed/18752540?ordinalpos=2&itool=EntrezSystem2.P
Entrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
(Please copy and paste into your web browser.)
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world byDerma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for themanagement of wounds and burns. The product has been shown to be effective ina variety of wounds and burns, and was recently the focus of a large-scalerandomized controlled trial on leg ulcers. Derma has two products indevelopment: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, thecompany's novel angiotensin analog for accelerated wound healing and scarreduction. The barrier technology was licensed from Quick-Med in Q1 of 2007and is pending its initial FDA marketing clearance. DSC127 was licensed fromThe University of Southern California in Q4 of 2007 and is entering into aPhase II study, with anticipated initial patient enrollment to begin in Q3 of2008. For more information about Derma Sciences, Inc., visit its home page onthe Internet at http://www.dermasciences.com.Contact: Derma Sciences, Inc. Allen & Caron Inc Edward J. Quilty Rudy Barrio (US Investors) Chairman and CEO [email protected] [email protected] (609) 514-4744 Brian Kennedy (media) [email protected] (212) 691-8087
SOURCE Derma Sciences, Inc.
